E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Active eosinophilic esophagitis |
Esofagitis eosinofilica activa |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic allergic/immune-mediated inflammatory disease of the gullet in its active phase |
Enfermedad alérgica/ inmune inflamatoria del esófago en fase activa |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064220 |
E.1.2 | Term | Eosinophilic esophagitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of budesonide effervescent tablets vs. placebo for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis (EoE). |
Evaluar la eficacia de comprimidos efervescentes de budesonida frente a placebo para la inducción de remisión clinicopatológica en pacientes adultos con esofagitis eosinofílica (EE) activa |
|
E.2.2 | Secondary objectives of the trial |
-To study safety and tolerability in the form of adverse events and laboratory parameters, -To assess patients quality of life. Exploratory: -To study biomarkers in EoE. |
-Estudiar la seguridad y la tolerabilidad en forma de acontecimientos adversos y parámetros analíticos. -Evaluar la calidad de vida del paciente -Estudiar los biomarcadores de la EE. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Signed informed consent, - Male or female patients, 18 to 75 years of age, - Confirmed clinico-pathological diagnosis of EoE according to established diagnostic criteria , - Active symptomatic and histological EoE, - A documented trial with proton pump inhibitors (PPIs) in order to rule out PPI-responsive esophageal eosinophilia, - Negative pregnancy test in females of childbearing potential at baseline visit |
-Firma del consentimiento informado. -Pacientes varones o mujeres de 18 a 75 años, ambos inclusive. -Diagnóstico clinicopatológico confirmado de EE según los criterios diagnósticos establecidos -EEA sintomática e histológica activa -Un ensayo documentado con inhibidores de la bomba de protones (IBP) para descartar eosinofilia esofágica sensible a los IBP -Prueba de embarazo negativa en mujeres en edad fértil en la visita inicial. |
|
E.4 | Principal exclusion criteria |
- Clinical signs (i.e., acid regurgitation and/or heart burn) and endoscopic signs (at least Los Angeles Classification of Esophagitis Grade A) of gastroesophageal reflux disease (GERD), - History of abnormal results in case of an optionally performed pH monitoring of the distal esophagus, - Patients with PPI-responsive esophageal eosinophilia - Achalasia, scleroderma esophagus, or systemic sclerosis, - Other clinically evident causes than EoE for esophageal eosinophilia, - Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection [candida esophagitis]), - Any relevant systemic disease (e.g., AIDS, active tuberculosis), - If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection, - Liver cirrhosis or portal hypertension, - History of cancer in the last five years, - History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit, - Upper gastrointestinal bleeding within 8 weeks prior to screening visit, - Existing or intended pregnancy or breast-feeding. |
-Signos clínicos (es decir, regurgitación ácida y/o acidez de estómago) y signos endoscópicos (al menos Grado A según la clasificación de esofagitis de Los Ángeles) de enfermedad de reflujo gastroesofágico (ERGE). -Antecedentes de resultados anómalos en caso de un control opcional del pH de la parte distal del esófago. -Pacientes con EES-IBP -Acalasia, esclerodermia esofágica o esclerosis sistémica. -Otras causas clínicamente evidentes distintas de la EE para la eosinofilia esofágica (es decir, enfermedad de Crohn, gastroenteritis eosinofílica, enfermedad del tejido conjuntivo, vasculitis, síndrome hipereosinofílico, enfermedad de injerto contra huésped, respuesta de hipersensibilidad farmacológica, infestación parasitaria [en los últimos 3 meses previos a la visita de la selección]). -Cualquier enfermedad esofágica concomitante y enfermedad gastrointestinal relevante (celiaquía, enfermedad inflamatoria intestinal, infección orofaríngea o esofágica bacteriana, vírica o fúngica [esofagitis por cándida]). -Cualquier enfermedad sistémica relevante (p. ej., sida, tuberculosis activa). -Si el control médico minucioso no está garantizado: enfermedad cardiovascular, diabetes mellitus, osteoporosis, enfermedad por úlcera péptica activa, glaucoma, cataratas o infección. -Cirrosis hepática o hipertensión portal. -Antecedentes de cáncer en los últimos 5 años. -Antecedentes de cirugía esofágica en cualquier momento o de procedimientos de dilatación esofágica en las 8 semanas previas a la visita de selección. -Embarazo existente o intención de quedarse embarazada o en período de lactancia. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Rate of patients with clinico-pathological remission |
Tasa de pacientes con remisión clinicopatológica |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Week 6 (LOCF) |
semana 6 (LOCF) |
|
E.5.2 | Secondary end point(s) |
- Rate of patients with histological remission, - Change from baseline in histology - Rate of patients with resolution of symptoms (i.e., no or only minimal problems of EoE). |
-Tasa de pacientes con remisión histológica -Cambio en el valor máximo entre el inicio y la semana 6 (LOCF). -Tasa de pacientes con resolución de los síntomas (es decir, ausencia de problemas o problemas mínimos) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Week 6 (LOCF) |
semana 6 (LOCF) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
6 week open label phase after 6 weeks of treatment for patients not having reached remission |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 45 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 14 |